Cargando…
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
The understanding of the B cell receptor (BCR) pathway and its contribution to chronic lymphocytic leukemia (CLL) pathogenesis have led to the development of targeted BCR inhibitors which have transformed the treatment paradigm of CLL. Ibrutinib is a first-in-class oral Bruton’s tyrosine kinase (BTK...
Autores principales: | Rhodes, Joanna M, Mato, Anthony R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936706/ https://www.ncbi.nlm.nih.gov/pubmed/33688166 http://dx.doi.org/10.2147/DDDT.S250823 |
Ejemplares similares
-
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia
por: An, Gang, et al.
Publicado: (2021) -
Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021) -
P609: EFFECT OF LONG-TERM ZANUBRUTINIB TREATMENT ON T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB-3111-304 AND 305 TRIALS.
por: Andersson, Maria, et al.
Publicado: (2023) -
Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
por: Montoya, Skye, et al.
Publicado: (2023) -
P1603: EFFICACY AND SAFETY OF BRUTON’S TYROSINE KINASE INHIBITOR ZANUBRUTINIB IN ITP
por: Huang, Qiu-Sha, et al.
Publicado: (2023)